EU antitrust regulators are set to approve Japanese drugmaker Takeda Pharmaceutical`s $62-billion offer for London peer Shire on condition that Shire sells a drug it has in development, a person familiar with the matter said on Friday.
Last month, Takeda offered to divest Shire`s pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.